°²öÎÓéÀÖ¹ÙÍø

°²öÎÓéÀÖ¹ÙÍøÑÛ¿Æ
Ä¿½ñλÖ㺠Ê×Ò³ > ¾ÍÕïÖ¸ÄÏ > ³£¼ûÑÛ²¡ÐÂÎÅ > ÕýÎÄ

·ÉÃ뼤¹â°×ÄÚÕÏÊÖÊõºóÊÓ¾õÖÊÁ¿Ñо¿

×÷ÕߣºÎ´Öª 2019-05-07 16:09:06
×ÖÌå´óС£º
¡¾µ¼¶Á¡¿·ÉÃ뼤¹â°×ÄÚÕÏÊÖÊõºóÊÓ¾õÖÊÁ¿Ñо¿

¡¡¡¡·ÉÃ뼤¹âÊÖÒÕµÄÒýÈëʹµÃ¹Å°åµÄ°×ÄÚÕÏÕª³ýÊÖÊõµÄÈô¸É°ì·¨×Ô¶¯»¯ £¬ Æä¸üºÃµÄ¾«*ÐԺͿÉÖØ¸´ÐÔ´øÀ´µÄ¿ÉÄܵÄÓÅÊÆ°üÀ¨ïÔÌ­²¢·¢Ö¢µÄ±¬·¢ºÍ¸üºÃµÄÊÓÁ¦¡£µ«ÓÉÓÚ¹ºÖúÍʹÓ÷ÉÃ뼤¹â°×ÄÚÕÏÊÖÊõÏà¹Ø×°±¸»á±¬·¢ÓöÈ £¬´Ó¹«¹²ÎÀÉúµÄ½Ç¶ÈÀ´¿´ £¬ÈôÊǸÃÊÖÊõÄÜÌá*Çå¾²ÐÔºÍÈ·¶¨ÐÔ £¬ïÔÌ­ÊõºóÌØÁíÍâÊÖÊõ¸ÉÔ¤ÐèÒª £¬¸ø»¼Õß´øÀ´¸üºÃµÄÊõºóЧ¹û £¬Ôò¸ÃÓöÈÎÊÌâ¿ÉÒÔ»ñµÃ»º½â¡£

¡¡¡¡ÓÉÓÚ°×ÄÚÕÏÊÖÊõÏà¹ØµÄ²»Á¼ÊÂÎñ±¬·¢ÂʽϵÍ £¬ÐèÒª´óÑù±¾µÄÑо¿²Å»ª³ä·ÖÌåÏÖFLACSºÍ¹Å°åÊÖÊõÔÚÇå¾²ÐÔÉϵIJî±ð¡£×èÖ¹ÏÖÔÚ½ÒÏþµÄ Ñù±¾Á¿µÄËæ»ú±ÈÕÕÑо¿(RCT) £¬¹²¼ÆÄÉÈë200Ö»ÑÛ £¬FLACS×鱨µÀǰÄÒĤ˺ÁÑ1  £¬FLACS×éºÍ¹Å°å³¬Èé×é¾ù䱨µÀÓкóÄÒÆÆË鱬·¢¡£ ½üһƪÀ´×Ô¿¼¿ÆÀ¶ (Cochrane)×ÛÂÛÄÉÈë16¸ö RCT¹²¼Æ1638Ö»ÑÛ £¬ Æä½áÂÛÖ¸³ö£º¼øÓÚÏÖÔÚȱ·¦×ã¹»´óÑù±¾µÄÑо¿Ö¤¾Ý £¬ÉÐÎÞ·¨¶Ï¶¨FLACSÏà±È¹Å°å³¬ÉùÊÖÊõµÄÀûÒæ»òȱ·¦¡£


¡¡¡¡Ñо¿Ä¿µÄ

¡¡¡¡±¾Ñо¿Îª×èÖ¹½ÒÏþʱ¼äΪֹ±ÈÕÕFLACSºÍ ¹Å°å³¬ÉùÈ黯ÊÖÊõ(Conventional Phacoemulsification Surgery , CPS)µÄ Ñù±¾µÄRCT £¬ ¼øÓÚ֮ǰµÄRCTÆÕ±éȱ·¦»¼Õß±¨¸æ µÄÆÀ¼Û(PROMs) £¬¸ÃÑо¿ÒýÈëÁËEuroQOL 5άµ÷ÅÌÎʾí(EQ-5D)ÓÃÓÚÆÀ¼Û»¼ÕßµÄÉúÑÄÖÊÁ¿ £¬ ½ÓÄÉÒ»¸ö°×ÄÚÕÏÊÖÊõµÄµ÷ÅÌÎʾí(Cataract surgery Patient-Reported Outcome Measures Questionnaire ,Cat-PROM5)ÆÀ¼Û»¼Õß±¨¸æµÄÊÓ¾õÖÊÁ¿¡£

¡¡¡¡Ñо¿ÒªÁì

¡¡¡¡Ñо¿Éè¼Æ£ºÇ°Õ°ÐÔ¡¢Ëæ»ú¡¢±ÈÕÕÑо¿¡£

¡¡¡¡Ñо¿ÒªÁ죺¹²ÄÉÈë400 »¼Õß400Ö»ÑÛ £¬ÆäÖÐ200Ö»ÑÛÐÐ FLACS £¬200Ö»ÑÛÐÐCPS¡£FLACS×éʹÓÃLenSx·ÉÃ뼤¹âÒ½ÖÎÒÇ(LenSx, Alcon Laboratories, Inc.) £¬ÓÉÁ½Î»½ÓÊÜ×°±¸Ê¹ÓÃÅàѵºÍ»ñµÃ¹Ù·½ÈÏÖ¤ £¬30 ÒÔÉÏÊõʽÂÄÀúµÄÊõÕßʵÑé¡£·ÉÃ뼤¹â±»ÓÃÓÚǰÄÒÇпª £¬ËéºËºÍÉ¢¹âÐÔ½ÇĤÇпªÊõ¡£·ÉÃ뼤¹âÔ¤´¦Öóͷ£ºó £¬»¼Õß±»×ªµ½ÊÖÊõ¼ä½ÓÄÉÖØÁ¦ÒºÁ÷Ť¶¯³¬Éù×°±¸(Infiniti, Alcon Laboratories, Inc.)Ðг¬ÉùÈ黯°×ÄÚÕÏÒÆ³ý¡£CPS×é²»½ÓÊÜ·ÉÃ뼤¹âÔ¤´¦Öóͷ£ £¬Ö±½ÓÐг¬ÉùÈ黯°×ÄÚÕÏÒÆ³ý¡£¹ØÓÚµØÐÎͼ½ÇĤɢ¹â´óÓÚ0.9DµÄ»¼Õß £¬FLACS×éÐзÉÃ뼤¹âÉ¢¹âÐÔ½ÇĤÇпªÊõ £¬CPS×éÐнÇĤԵËɽâÇÐ¿Ú É¢¹â¡£ËùÓл¼ÕßĬÈÏÖ²ÈëÊèË®ÐÔ±ûÏ©Ëáõ¥È˹¤¾§Ìå(Acrysof SA60AT, Alcon Laboratories, Inc.)¡£

¡¡¡¡Êý¾ÝÍøÂç

       Êõǰ»ùÏßÌØÕ÷Êý¾Ý(°üÀ¨UDVA(ÂãÑÛÔ¶ÊÓÁ¦), CDVA( Ô¶ÊÓÁ¦),С¿×ÊÓÁ¦(PHVA), IOP,°×ÄÚÕÏÊÖÊõΣº¦ÒòËØ £¬Çü¹â²»ÕýÇéÐÎ £¬½ÇĤÇúÂÊÕÉÁ¿ £¬ÉúÎïÕÉÁ¿ÊÖÊõÈÕ¼°Êõºó 3-4ÖÜËæ·ÃµÄ²»Á¼ÊÂÎñÇéÐÎ £¬Êõºó3-4ÖÜ Ëæ·Ã¼ì²éÇü¹â²»ÕýÇéÐÎ £¬½ÇĤµØÐÎͼ £¬ÄÚÆ¤Ï¸°û¼ÆÊý(ECC) £¬»Æ°ßOCT £¬EQ-5D-3L(EuroQOL 5άµ÷ÅÌÎʾí £¬µÚÈý¼¶°æ) £¬Cat-PROM5¡£

¡¡¡¡½¹µã¿´·¨

¡¡¡¡1.FLACS×éºÍCPS×éÏà±ÈÄ¿µÄÇü¹â¶ÈµÄ µÈЧÇò¾µÇü¹âÎó²îÁ½ÕßûÓÐ ²î±ð;

¡¡¡¡2.Cat-PROM5Ч¹ûÏÔʾÁ½×éÊõǰÊõºóÊÓÁ¦ ¾ù  £¬µ«Á½×éµÄת±äÀàËÆ £¬EQ-5D¹éÄÉ×ÛºÏÖ¸ÊýÏÔʾÁ½×éµÄ·ÖÊýÌáÉýͬÑùÀàËÆ;

¡¡¡¡3.Á½×éµÄÊõÖм°Êõºó×ܲ¢·¢Ö¢±¬·¢ÂÊÎÞ ²î±ð £¬ÆäÖÐÁ½×éÊõºó»Æ°ßÄÒÑùË®Ö×(CME)±¬·¢ÂÊÎÞ ²î±ð £¬µ«ÊõÖеĺóÄÒÆÆËéÂÊCPS×é ¸ßÓÚFLACS×é(P=0.03);

¡¡¡¡Ñо¿½áÂÛ

¡¡¡¡×èÖ¹ÎÄÕÂͶ¸åΪֹ £¬ÕâÊDZÈÕÕFLACSºÍCPSÇå¾²ÐÔºÍ Ð﵀ Ñù±¾µÄRCT £¬±¾Ñо¿Ö¤ÊµFLACSºÍCPSÊõºóÖÜÎ§Ëæ·ÃÔÚÊÓÁ¦ÌáÉý¡¢ÑÛѹÉý¸ßÁ½ÕßÎÞ ²î±ð £¬FLACSºÍCPSͬÑùÇå¾² ¡£Ê×´ÎÔÚRCTÖÐ֤ʵÁ½×éCME±¬·¢ÂÊÎÞ ²î±ð £¬CPS×éÊõÖÐÆÆºóÄÒĤÂÊ ¸ßÓÚFLACS×é £¬FLACS¿ÉÄÜÔÚ¸ßÆÆºóÄÒĤΣº¦²¡ ÖÐÕ¹ÏÖÓÅÊÆ¡£

ÔÚÏß×Éѯ
·µ»Ø
?
  • »ª±±µØÇø
  • »ªÄϵØÇø
  • Î÷ÄϵØÇø
  • »ªÖеØÇø
  • »ª¶«µØÇø
  • Î÷±±µØÇø
  • ¶«±±µØÇø
°²öÎÓéÀÖ¹ÙÍøÑÛ¿ÆÎ¢ÐŹ«ÖںŠ΢ÐŹ«ÖÚºÅ
΢²©
ÍøÕ¾µØÍ¼